151
|
Tan M, Huisman MV. The diagnostic management of acute venous thromboembolism during pregnancy: recent advancements and unresolved issues. Thromb Res 2011; 127 Suppl 3:S13-6. [PMID: 21262431 DOI: 10.1016/s0049-3848(11)70005-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Adequate diagnostic management of suspected venous thromboembolism (VTE) in pregnant women is of great importance. The diagnostic performance of clinical decision rules and D-dimer testing is influenced by physiological changes during pregnancy and is understudied. Recent studies have addressed these issues by developing a new clinical decision rule and raising the D-dimer level cut-off points. With imaging of suspected pulmonary embolism (PE) the radiation exposure remains a concern. Recent studies have adjusted CT settings and scan length to minimize this exposure without loss of image quality. Furthermore the first choice imaging modality of suspected PE in pregnant women remains a matter of debate in view of studies showing high inadequacy rates for both CT scanning and VQ scanning. Issues concerning the diagnostic management of VTE in pregnant women and advancements made in recent years will be discussed.
Collapse
Affiliation(s)
- M Tan
- Section of Vascular Medicine, Department of General Internal Medicine-Endocrinology, Leiden University Medical Center, Leiden.
| | | |
Collapse
|
152
|
Leong KTG, Cao Y, Tan M. HEART FAILURE PROGRAM IN AN ASIAN MULTI-ETHNIC ACUTE HEART FAILURE COHORT AND OUTCOMES. J Am Coll Cardiol 2011. [DOI: 10.1016/s0735-1097(11)60391-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
153
|
Heng DY, MacKenzie MJ, Vaishampayan UN, Knox JJ, Bjarnason GA, Tan M, Wood L, Donskov F, Rini BI, Choueiri TK. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.305] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
305 Background: A proportion of patients treated with anti-VEGF therapy first line exhibit progressive disease (PD) as best response (per RECIST). The characteristics and outcome of this population are poorly understood. Methods: Data from patients with mRCC treated with anti-VEGF therapy were collected through the International mRCC Database Consortium from 12 centers. Results: One thousand fifty-six evaluable patients were treated with VEGF-inhibitors as their first-line antiangiogenic therapy. Of those, 272 (26%) patients had PD as best response. Their initial treatment was sunitinib (n=203), sorafenib (n=51), or bevacizumab (n=18). Six percent of patients were favorable risk, 55% intermediate risk, and 39% poor risk as per Heng et al JCO 2009 prognostic factors. On multivariable analysis, predictors of PD at first restaging were KPS < 80% (OR 2.3, p < 0.0001), diagnosis to treatment < 1 year (OR 2.1, p < 0.0001), neutrophilia (OR 1.9, p = 0.0021), thrombocytosis (OR 1.7, p = 0.0068), and anemia (OR 1.6, p = 0.0058). The median progression-free survival (PFS) and overall survival (OS) in patients with primary refractory disease vs. patients without (i.e., partial response or stable disease) was 2.4 vs. 11 months (p<0.0001) and 6.8 vs. 29 months (p<0.0001), respectively. Only 108 (40%) VEGF-refractory patients proceeded to receive 2nd line VEGF inhibitors (sunitinib (n=32), sorafenib (n=44), axitinib (n=2), bevacizumab (n=4)), mTOR inhibitors (temsirolimus (n=14), everolimus (n=11)), or interferon (n=1). The response rate, PFS and OS of this second-line therapy was 9%, 2.5 months and 7.4 months, respectively. The response rate, PFS and OS of those receiving second-line VEGF vs. mTOR inhibitors was 10% vs. 6% (p=NS), 2.8 vs. 2.0 months (p=0.069) and 7.9 vs. 4.7 months (p=0.40), respectively. Conclusions: Primary anti-VEGF-refractory mRCC patients have a dismal prognosis. Second-line anti-mTOR agents may not be better than alternate anti-VEGF agents after primary anti-VEGF failure. Investigation into the mechanism of primary resistance and alternative therapeutic strategies are needed. [Table: see text]
Collapse
Affiliation(s)
- D. Y. Heng
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | - M. J. MacKenzie
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | - U. N. Vaishampayan
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | - J. J. Knox
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | - G. A. Bjarnason
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | - M. Tan
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | - L. Wood
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | - F. Donskov
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | - B. I. Rini
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | - T. K. Choueiri
- Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; London Regional Cancer Program, London, ON, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Princess Margaret Hospital, Toronto, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; National Cancer Centre Singapore, Singapore, Singapore; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Cleveland Clinic Taussig Cancer
| | | |
Collapse
|
154
|
Wong M, Yip C, Hou X, Tan P, Huang H, Chowbay B, Lau W, Tan T, Tan M, Wong F. Validation of the AJCC staging system (7th edition) in Asian patients with localized prostate cancer undergoing radical radiotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
112 Background: The epidemiology of prostate cancer (PCa) varies widely internationally. Although prostate cancer is usually regarded as uncommon in Asia, dramatic rises in recent years have resulted in it being ranking third by incidence in Singapore. Conventional prognostic parameters derived from Western populations have been integrated into systems such as the new AJCC seventh edition staging system, the validity of which is unclear in Asia. We thus sought to validate its performance, alongside other prognostic factors in a large Asian series of radiotherapy patients. Methods: A retrospective review of 404 consecutive Singaporean patients receiving radical radiotherapy between 1997 and 2005 at the National Cancer Centre was performed. The primary outcome was biochemical relapse free survival (BRFS), defined by the Phoenix criteria. Prognostic risk groups were defined using AJCC seventh edition. Univariate analysis (UVA) and multivariate analysis (MVA) was performed for other putative risk factors: age, race, Gleason score, prognostic risk grouping, tumour classification, radiation delivery technique, radiotherapy dose, hormonal therapy (HT) and initial PSA. Results: Median age was 69; median BRFS was 55 months with 71 biochemical relapses. 4 risk factors showed univariate association with BRFS: AJCC risk groups (p=0.038), T-stage (p=0.018), RT dose (p=0.025) and initial PSA value (p=0.013) with AJCC risk groups and initial PSA value remaining significant after MVA ( Table ). Harrell's c-index for AJCC risk grouping was 0.56, with no significant difference seen in outcomes between AJCC risk group II and III. Conclusions: Our results validate the new AJCC seventh edition prostate cancer prognostic risk grouping in an Asian radiotherapy population for the first time; the actual association however is relatively weak possibly due to differences in biology, screening or epidemiology. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Wong
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - C. Yip
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - X. Hou
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - P. Tan
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - H. Huang
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - B. Chowbay
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - W. Lau
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - T. Tan
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - M. Tan
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| | - F. Wong
- National Cancer Centre Singapore, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore
| |
Collapse
|
155
|
Schutz FA, Xie W, Heng DY, Donskov F, Wood L, Vaishampayan UN, Tan M, MacKenzie MJ, Kollmannsberger CK, Choueiri TK. The effect of low serum sodium on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.322] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
322 Background: Hyponatremia has been associated with poor survival in many solid tumors and more recently found to be of prognostic and predictive value in metastatic renal cell cancer (mRCC) patients (pts) treated with immunotherapy (Jeppesen et al, Br J Cancer. 2010). We sought to investigate the influence of baseline hyponatremia in mRCC pts treated with contemporary vascular endothelial growth factor (VEGF)- targeted therapy in a larger international and multi-institutional database. Methods: Baseline characteristics and outcomes on 855 pts treated with first-line anti-VEGF therapy for mRCC were available from 8 Cancer Centers to study the impact of hyponatremia (defined as serum Na<135 mmol/L) on clinical outcome as measured by overall survival (OS), time to treatment failure (TTF), best response (CR, PR, SD and PD). Results: Median OS after treatment initiation was 16.8 months (mos) (95% CI: 14.9, 18.5 mos), with 334 (39%) of patients remaining alive. Median follow-up in pts alive was 18.8 mos. Median baseline serum sodium was 138 mmol/L (range: 122–159), and hyponatremia was found in 16.7% of pts. On univariate analysis, hyponatremia was associated with shorter OS (6.5 vs. 18.8 mos; HR 2.32 [95% CI: 1.86–2.89], p<0.0001), shorter TTF (2.8 vs. 6.9 mos.; HR 2.20 [95% CI: 1.81–2.68], p<0.0001), and lower disease control rate (DCR) as defined by CR+PR+SD (51.2% vs. 74.6%, OR 0.36 [95% CI: 0.2–0.57], p<0.0001). In multivariate analysis adjusted for MSKCC or Heng's risk criteria (JCO 2009), these effects remain significant with p<0.001 for OS and TTF and p=0.01 for DCR. The results were similar (p<0.001) if sodium was analyzed as a continuous variable. Conclusions: This is the first large multi-institutional report to show that low serum sodium is independently associated with a worse outcome in mRCC pts treated with VEGF-targeted agents. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. A. Schutz
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| | - W. Xie
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| | - D. Y. Heng
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| | - F. Donskov
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| | - L. Wood
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| | - U. N. Vaishampayan
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| | - M. Tan
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| | - M. J. MacKenzie
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| | - C. K. Kollmannsberger
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| | - T. K. Choueiri
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; National Cancer Centre Singapore, Singapore, Singapore; London Regional Cancer Program, London, ON, Canada; Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver
| |
Collapse
|
156
|
Leong K, Cao Y, Buhari S, Yeo Y, Poh K, Tan M, Goh P. A011 Heart Failure with Preserved Left Ventricular Ejection Systolic Function and Outcomes in a Disease Management Acute Heart Failure Program in a Multi-Ethnic Asian Community. Int J Cardiol 2011. [DOI: 10.1016/s0167-5273(11)70016-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
157
|
Goh P, Ong S, Tan M. P002 Impact of Gender on Utilisation Pattern of Key Medications after Acute Myocardial Infarction. Int J Cardiol 2011. [DOI: 10.1016/s0167-5273(11)70025-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
158
|
Oto A, Ergene O, Erol M, Kucukoglu S, Ozdemir O, Tan M. OP-099: COMPARING THE COST-EFFECTIVENESS OF IVABRADINE WITH ISOSORBIDE MONONITRATE, AMLODIPINE, DILTIAZEM AND VERAPAMIL, IN THE TREATMENT OF STABLE ANGINA PECTORIS. Int J Cardiol 2011. [DOI: 10.1016/s0167-5273(11)70185-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
159
|
Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22:1071-1077. [PMID: 21317223 DOI: 10.1093/annonc/mdr006] [Citation(s) in RCA: 347] [Impact Index Per Article: 26.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND The association between human papillomavirus (HPV) and overall survival (OS) in oropharynx cancer (OPC) was retrospectively examined in TAX 324, a phase III trial of sequential therapy for locally advanced head and neck cancer. METHODS Accrual for TAX 324 was completed in 2003 and data updated through 2008. Pretherapy tumor biopsies were studied by PCR for human papillomavirus type 16 and linked to OS, progression-free survival (PFS) and demographics. RESULTS Of 264 patients with OPC, 111 (42%) had evaluable biopsies; 56 (50%) were HPV+ and 55 (50%) were HPV-. HPV+ patients were significantly younger (54 versus 58 years, P = 0.02), had T1/T2 primary cancers (49% versus 20%, P = 0.001), and had a performance status of zero (77% versus 49%, P = 0.003). OS and PFS were better for HPV+ patients (OS, hazard ratio = 0.20, P < 0.0001). Local-regional failure was less in HPV+ patients (13% versus 42%, P = 0.0006); at 5 years, 82% of HPV+ patients were alive compared with 35% of HPV- patients (P < 0.0001). CONCLUSIONS HPV+ OPC has a different biology compared with HPV- OPC; 5-year OS, PFS, and local-regional control are unprecedented. These results support the possibility of selectively reducing therapy and long-term morbidity in HPV+ OPC while preserving survival and approaching HPV- disease with more aggressive treatment.
Collapse
Affiliation(s)
- M R Posner
- The Tisch Cancer Institute, Mount Sinai Medical Center, New York.
| | - J H Lorch
- Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - O Goloubeva
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore
| | - M Tan
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore
| | - L M Schumaker
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore
| | | | - R I Haddad
- Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - K J Cullen
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore
| |
Collapse
|
160
|
Yan AT, Yan RT, Cantor WJ, Borgundvaag B, Cohen EA, Fitchett DH, Dzavik V, Ducas J, Tan M, Casanova A, Goodman SG. Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Eur Heart J 2011; 32:1994-2002. [DOI: 10.1093/eurheartj/ehr008] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|
161
|
Ng E, Ang S, Li H, Lim K, Choo S, Ngeow JY, Toh H, Chow PK, Tan M. The Singapore liver cancer recurrence (SLICER) score for relapse prediction in patients with resected hepatocellular carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
169 Background: Hepatocellular carcinoma (HCC) is a common worldwide cancer associated with extremely poor survival, with surgery the only option for cure in patients with localized disease. Current prognostic models for HCC are algorithms developed on datasets of mainly patients with metastatic or unresectable cancer, and may be less relevant to resectable HCC. Nomograms provide individualized outcome estimates. We constructed a postoperative nomogram, the Singapore liver cancer recurrence (SLICER) score, to predict outcomes of HCC patients who have undergone surgical resection. Methods: Records for Singaporean patients undergoing first-line curative surgery for localized HCC in one institution between 1992 and 2007 were retrospectively reviewed (n=405). Freedom from relapse (FFR) was the primary outcome measure. An outcome-blinded modeling strategy including clustering, data reduction and transformation, was used. Calibration was tested with bootstrapping (n=200). We compared the performance of this model with other alternative models including CLIP, CUPI, BCLC, and Okuda scores using c-indices and likelihood analysis. Results: A nomogram (SLICER score) predicting FFR was designed, incorporating vascular invasion, tumor size, multifocality, ECOG status, pre-operative AFP, Childs-Pugh score and cirrhosis. Bootstrap estimates show good calibration at 1, 2, 3, and 5 years postsurgery Comparison of the SLICER score with alternative prognostic models shows superior performance (Table). Conclusions: The SLICER score enables individualized relapse predictions for patients following curative resection of localized HCC. It permits optimal patient selection for adjuvant therapy trials, biomarker development, and individual counseling. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Ng
- Singapore General Hospital, Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore, Singapore; National Cancer Centre Singapore, Singapore, Singapore
| | - S. Ang
- Singapore General Hospital, Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore, Singapore; National Cancer Centre Singapore, Singapore, Singapore
| | - H. Li
- Singapore General Hospital, Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore, Singapore; National Cancer Centre Singapore, Singapore, Singapore
| | - K. Lim
- Singapore General Hospital, Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore, Singapore; National Cancer Centre Singapore, Singapore, Singapore
| | - S. Choo
- Singapore General Hospital, Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore, Singapore; National Cancer Centre Singapore, Singapore, Singapore
| | - J. Y. Ngeow
- Singapore General Hospital, Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore, Singapore; National Cancer Centre Singapore, Singapore, Singapore
| | - H. Toh
- Singapore General Hospital, Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore, Singapore; National Cancer Centre Singapore, Singapore, Singapore
| | - P. K. Chow
- Singapore General Hospital, Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore, Singapore; National Cancer Centre Singapore, Singapore, Singapore
| | - M. Tan
- Singapore General Hospital, Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore, Singapore; National Cancer Centre Singapore, Singapore, Singapore
| |
Collapse
|
162
|
Yang B, Chen M, Zhang F, Ju W, Chen H, Zhai L, Yang H, Wang J, Yu J, Shan Q, Zou J, Chen C, Hou X, Cao K, Chi SY, Ho D, Wong SP, Prasertwitayakij N, Vodnala D, Pridjian AK, Thakur RK, Tan VH, Lee L, Wah LB, Tan M, Khurana R, Liew R, Chow J, Madras A, Arena F, Barin E, Figtree G. Case Reports I. Europace 2011. [DOI: 10.1093/europace/euq486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
163
|
Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker L, Sarlis NJ, Haddad RI, Cullen KJ. Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5525] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
164
|
Heng DY, Xie W, Bjarnason GA, Vaishampayan UN, Donskov F, Wood L, Knox JJ, Tan M, Kollmannsberger CK, Rini BI, Choueiri TK. A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4523] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
165
|
Mehnert JM, Hausner PF, Tan M, Weber D, Sausville EA. Treatment of melanoma with wild-type p53 (wtp53) and detectable S100B using pentamidine: A phase II trial with correlative biomarker endpoints. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps310] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
166
|
Tan M, Velthuis SI, Westerbeek RE, VAN Rooden CJ, VAN DER Meer FJM, Huisman MV. High percentage of non-diagnostic compression ultrasonography results and the diagnosis of ipsilateral recurrent proximal deep vein thrombosis. J Thromb Haemost 2010; 8:848-50. [PMID: 20398187 DOI: 10.1111/j.1538-7836.2010.03758.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
167
|
Matrone MA, Whipple RA, Thompson K, Cho EH, Vitolo MI, Balzer EM, Yoon JR, Ioffe OB, Tuttle KC, Tan M, Martin SS. Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells. Oncogene 2010; 29:3217-27. [PMID: 20228842 DOI: 10.1038/onc.2010.68] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The cytoskeletal organization of detached and circulating tumor cells (CTCs) is currently not well defined and may provide potential targets for new therapies to limit metastatic tumor spread. In vivo, CTCs reattach in distant tissues by a mechanism that is tubulin-dependent and suppressed by polymerized actin. The cytoskeletal mechanisms that promote reattachment of CTCs match exactly with the mechanisms supporting tubulin microtentacles (McTN), which we have recently identified in detached breast tumor cells. In this study, we aimed to investigate how McTN formation is affected by the microtubule-associated protein, tau, which is expressed in a subset of chemotherapy-resistant breast cancers. We demonstrate that endogenous tau protein localizes to McTNs and is both necessary and sufficient to promote McTN extension in detached breast tumor cells. Tau-induced McTNs increase reattachment of suspended cells and retention of CTCs in lung capillaries. Analysis of patient-matched primary and metastatic tumors reveals that 52% possess tau expression in metastases and 26% display significantly increased tau expression over disease progression. Tau enrichment in metastatic tumors and the ability of tau to promote tumor cell reattachment through McTN formation support a model in which tau-induced microtubule stabilization provides a selective advantage during tumor metastasis.
Collapse
Affiliation(s)
- M A Matrone
- Program in Molecular Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
168
|
Tan M, Teh H. Abstract No. 338: Effects on IVC diameters in normal subjects with respiration. J Vasc Interv Radiol 2010. [DOI: 10.1016/j.jvir.2009.12.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
169
|
Tan M, Huisman MV. Point-of-care D-dimer tests can contribute to patient management in outpatients with suspected venous thromboembolism, particularly those at low risk. Evid Based Med 2010; 15:28. [PMID: 20176884 DOI: 10.1136/ebm.15.1.28] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Affiliation(s)
- M Tan
- Department of General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
| | | |
Collapse
|
170
|
Tan M, Velthuis SI, Westerbeek RE, Van Rooden CJ, Van Der Meer FJM, Huisman MV. High percentage of non-diagnostic compression ultrasonography results and the diagnosis of ipsilateral recurrent proximal deep vein thrombosis. J Thromb Haemost 2010. [DOI: 10.1111/j.1538-7933.2010.03758.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
171
|
McEvoy K, Tan M, Vishwanath L. Breast conserving surgery for invasive lobular breast cancer often requires completion mastectomy. Eur J Surg Oncol 2009. [DOI: 10.1016/j.ejso.2009.07.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
172
|
Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W, Guo Y. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 2009; 28:3412-22. [PMID: 19597469 DOI: 10.1038/onc.2009.189] [Citation(s) in RCA: 237] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Angiogenesis is a key step in tumor growth and metastasis. The mechanism by which osteopontin (OPN) induces the angiogenesis of endothelial cells remains unclear. Here, we show that OPN confers cytoprotection through the activation of the PI3K/Akt pathway with subsequent upregulation of Bcl-xL and activation of nuclear factor-kappaB. OPN enhances the expression of vascular endothelial growth factor (VEGF) through the phosphorylation of AKT and extracellular signal-regulated kinase (ERK). In turn, OPN-induced VEGF activates PI3K/AKT and the ERK1/2 pathway as a positive feedback signal. Blocking the feedback signal by anti-VEGF antibody, PI3-kinase inhibitor or ERK inhibitor can partially inhibit the OPN-induced human umbilical vein endothelial cell (HUVEC) motility, proliferation and tube formation, while blocking the signal by anti-OPN or anti-alphavbeta3 antibody completely abrogates the biological effects of OPN on HUVECs. In addition, blood vessel formation is also investigated in vivo. The antiangiogenesis efficacy of anti-OPN antibody in vivo is more effective than that of anti-VEGF antibody, which only blocks the feedback signals. These data show that OPN enhances angiogenesis directly through PI3K/AKT- and ERK-mediated pathways with VEGF acting as a positive feedback signal. The results suggest that OPN might be a valuable target for developing novel antiangiogenesis therapy for treatment of cancer.
Collapse
Affiliation(s)
- J Dai
- International Joint Cancer Institute and General Hospital Cancer Center, The Second Military Medical University, Shanghai, PR China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
173
|
Tkaczuk KH, Tait NS, Ioffe O, Tan M, Mohiuddin M, Chumsri S, VanEcho DA, Sutula MJ, Lesko S, Deamond S, Ts'o P. Drug Response Indicator Test (DRIT) as a predictive test for treatment outcomes in advanced breast cancer patients (ABC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1119 Background: There are limited options for selecting an optimal treatment regimen for ABC patients (pts). DRIT is a platform technology that provides a profile of a patient's tumor's sensitivity or resistance to commonly used chemotherapeutic, hormonal, or biological agents as a basis for individualized anticancer treatment approach. DRIT may allow physicians to choose more effective drug treatments before initiation of therapy and improve the efficacy and toxicity profile of cancer therapies. Methods: DRIT analysis is based on fluorescent dye-labeled monoclonal antibody staining followed by computer-assisted microscopy to quantitatively measure expression levels in tumor sections. The interpretation of DRI expression levels results in classification of tumors as sensitive or resistant to treatment with a mechanistically related drug. This study utilized the following drug/DRI combinations: hormonal therapy/estrogen receptor; capecitabine/thymidylate synthase; docetaxel, paclitaxel, abraxane/β-tubulin isoform III; trastuzumab/HER-2; gemcitabine/ribonucleotide reductase. DRIT was performed on the tumor tissue of consented study participants with ABC who were then deemed to be sensitive or resistant to a given agent/agents. We then analyzed retrospectively clinical treatment outcomes (clinically sensitive to therapy defined as-stable disease+partial response+complete response or resistant to therapy-no response to therapy) for 91 treatment interventions in 71 pts with the DRIT tissue data. Results: We found that the DRIT sensitivity was 0.99, with specificity of 0.59, positive predictive value of 0.88, negative predictive value of 0.93 and overall predictive value of 88% for treatment outcomes for this cohort of ABC pts. Conclusions: This study suggests that DRIT can provide more accurate prediction of treatment outcomes for ABC pts than the standard of care approach and therefore has a potential to avoid unnecessary ineffective drug treatment exposure. Prospective study in ABC pts is currently conducted at the UMGCC. [Table: see text]
Collapse
Affiliation(s)
- K. H. Tkaczuk
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - N. S. Tait
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - O. Ioffe
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - M. Tan
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - M. Mohiuddin
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - S. Chumsri
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - D. A. VanEcho
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - M. J. Sutula
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - S. Lesko
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - S. Deamond
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - P. Ts'o
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| |
Collapse
|
174
|
Cruz MC, Tan M. Epidermal growth factor receptor inhibitors as second-line treatment in advanced non-small cell lung cancer: A meta-analysis. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7597 Background: Overall survival in lung cancer remains poor despite availability of chemotherapy, which is limited by its toxicity and drug resistance. Advancement in research resulted to the development of targeted therapies, specifically epidermal growth factor receptor (EGFR) inhibitors. Results of clinical studies on survival benefits of EGFR inhibitors were conflicting although beneficial improvements in the quality of life and adverse effects were consistently demonstrated. The aim of our study is to determine the overall survival benefit of EGFR inhibitors alone or in combination with chemotherapy in second-line treatment of advanced non-small cell lung cancer (NSCLC). Methods: We did a meta-analysis of all randomized controlled trials involving patients with advanced NSCLC who failed at least one prior chemotherapy and were given EGFR inhibitor alone or in combination with chemotherapy compared to placebo or chemotherapy, with overall survival as an outcome. Pre-planned subgroup analysis was done on studies comparing EGFR to placebo and chemotherapy.Results: Five of the six trials included were analyzed for overall survival involving 4482 patients. Treatment with EGFR tyrosine kinase inhibitor (TKI) showed a trend towards significant survival benefit (RR=0.96, 95% CI 0.93–1.00, p=0.04) compared to placebo or chemotherapy. Preplanned subgroup analysis demonstrated significant survival benefit with EGFR-TKI versus placebo (RR=0.92, 95% CI 0.86–0.97, p=0.003) but comparable efficacy with chemotherapy (RR=1, 95% CI 0.96–1.06, p=0.84).Conclusions: Second-line treatment with EGFR-TKI demonstrated significant survival benefit versus placebo and comparable survival effect to chemotherapy. Further research should be done to identify patients’ characteristics associated with good treatment response. [Table: see text]
Collapse
Affiliation(s)
- M. C. Cruz
- Chinese General Hospital and Medical Center, Manila, Philippines; College of Medicine UP PGH, Manila, Philippines
| | - M. Tan
- Chinese General Hospital and Medical Center, Manila, Philippines; College of Medicine UP PGH, Manila, Philippines
| |
Collapse
|
175
|
Pandya NB, Tkaczuk KR, Tait N, Ioffe O, Tan M, Van Echo DA, Sutula MJ, Lesko SA, Deamond SF, Ts’o PO. A predictive test for therapeutic treatment outcomes of advanced gastrointestinal cancer patients (AGC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15079 Background: There are currently limited options for selecting an optimal treatment regimen for AGC patients. The Drug Response Indicator Test (DRIT) is a platform technology that provides a detailed profile of a patient's tumor response to commonly used chemotherapeutic drugs, as a basis for individualized treatment. Establishment of DRIT will allow physicians to choose effective drug treatments to improve the efficacy of cancer therapies on an individual basis. Methods: DRIT analysis is based on fluorescent dye-labeled monoclonal antibody staining followed by computer-assisted microscopy to measure expression levels in tumor sections. The interpretation of the Drug Response Indicator (DRI) expression levels result in classification of tumors as sensitive or resistant to treatment with a mechanistically related drug. Clinical outcomes are then analyzed with respect to the DRI data. This study utilized the following drug/DRI combinations: capecitabine, 5-flurouracil/thymidylate synthase; docetaxel, paclitaxel, abraxane/β-tubulin isoform III; gemcitabine/ribonucleotide reductase; platinum salts/ERCC-1; Irinotecan/Topoisomerase I. Results: DRIT retrospective studies were performed on a cohort of 33 consented patients (pts) receiving 55 treatments for AGC at UMGCC. This cohort included pts treated for rectal/colon, gastric, esophageal & pancreatic cancers. DRIT sensitivity was 0.96, positive predictive value 0.84, negative predictive value 0.67 and overall predictive accuracy 83 %. DRI expression level cut-off points indicating sensitivity or resistance to a specific treatment were derived from previous retrospective breast cancer studies using similar drug complements (abstract 6075 San Antonio Breast Conference 2008). Conclusions: This study indicates that DRIT can provide accurate prediction of treatment outcomes for individual AGC patients. DRI expression level cut-off points indicating sensitivity or resistance to a specific treatment may be applied to both breast cancer & AGC. DRIT will allow for tailoring of chemotherapy based on the specific biomarker expression within each patient's tumor tissue. [Table: see text]
Collapse
Affiliation(s)
- N. B. Pandya
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - K. R. Tkaczuk
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - N. Tait
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - O. Ioffe
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - M. Tan
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - D. A. Van Echo
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - M. J. Sutula
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - S. A. Lesko
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - S. F. Deamond
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| | - P. O. Ts’o
- University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics LLC, Baltimore, MD
| |
Collapse
|
176
|
Yılmaz R, Öz E, Tan M, Durak R, Demirel A, Şahin Y. Measurements of Coster–Kronig enhancement factors for Yb, Lu, Os and Pt elements. Radiat Phys Chem Oxf Engl 1993 2009. [DOI: 10.1016/j.radphyschem.2009.02.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
177
|
Boyce P, Huang Soo Lee M, Jenkins C, Mohamed S, Overs C, Paiva V, Reid E, Tan M, Aggleton P. Putting sexuality (back) into HIV/AIDS: issues, theory and practice. Glob Public Health 2009; 2:1-34. [PMID: 19280385 DOI: 10.1080/17441690600899362] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
After more than twenty years of programming and activism aimed at stemming the sexual transmission of HIV (and addressing the needs of those most vulnerable to infection) the HIV/AIDS epidemic continues to grow worldwide. Taking up this concern, this paper argues that one of the reasons why HIV prevention has had limited success is because of inadequate conceptualization of human sexuality in such work. Giving sexuality a more prominent position in responses to the epidemic raises a range of issues, including theorization of gender, understanding of sexual subjectivity, the significance of pleasure (or lack of pleasure) in sexual decision-making, and conceptualization of sexual behaviour and culture. Taking these themes forward entails asking significant questions about the underlying paradigmatic and methodological commitments of mainstream HIV/AIDS research, especially the tendency to reproduce accounts of human sexuality as if it were a measurable form of conduct only. Advocating new approaches that take the meaning and symbolic value of sexualities into account complicates established orthodoxies in the field whilst offering potential for more effective HIV prevention strategies.
Collapse
Affiliation(s)
- P Boyce
- Thomas Coram Research Unit, Institute of Education, University of London, London, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
178
|
Tan NC, Tay IH, Ngoh A, Tan M. Factors influencing family physicians' drug prescribing behaviour in asthma management in primary care. Singapore Med J 2009; 50:312-319. [PMID: 19352577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
INTRODUCTION Little is known about the decision pathway that family physicians (FP) take in considering drug therapy for their asthma patients. This study aimed to explore the factors that influence FPs' decisions in prescribing medications for their asthma patients. METHODS A qualitative method using focus group discussions (FGD) was used to gather qualitative data based on a semi-structured topic guide from FPs of different training backgrounds and practices. 29 Singapore FPs working as private general practitioners (GP), polyclinic doctors and locums were recruited into five FGDs. RESULTS The FPs' asthma drug prescription decisions were related to the FPs' medical training and acquisition of asthma-related information and updates. Uncertainty of disease diagnosis, patients' beliefs and their perceptions of the disease and treatment, as well as the FPs' concerns about drug side effects, were significant considerations for the participants. Costs related to differential subsidies in the consultation fees and drugs between public polyclinics and GP clinics in the local primary healthcare system, was a key factor in influencing the FPs' asthma drug treatment decisions. CONCLUSION FPs' asthma drug prescribing behaviour is influenced by their medical training, disease definition, patient factors and drug costs in the context of the local primary healthcare system and policy.
Collapse
Affiliation(s)
- N C Tan
- SingHealth Polyclinics - Pasir Ris, Pasir Ris Drive 4, #01-11, Singapore 519457.
| | | | | | | |
Collapse
|
179
|
Tan NC, Tay IH, Ngoh A, Tan M. A qualitative study of factors influencing family physicians' prescription of the Written Asthma Action Plan in primary care in Singapore. Singapore Med J 2009; 50:160-164. [PMID: 19296031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
INTRODUCTION The Written Asthma Action Plan (WAAP) educates patients on the early recognition and treatment of deteriorating asthma. It has been adopted in Singapore polyclinics and restructured hospitals in the past few years as recommended by the Singapore National Asthma Programme. Local asthma patients can choose to be treated by family physicians at public polyclinics or by private general practitioners (GPs). In a previous study, half of the physicians in primary care self-reported that they formulated an asthma action plan for their patients, but little is known about their actual practices. This qualitative study explored family physicians' views of WAAP and its implementation in primary care in Singapore. METHODS Qualitative data was obtained for 29 participants from polyclinics, GP clinics or locum doctors at five separate focus group discussions. The data was coded using NVivo-7 software, audited and analysed to identify emergent themes. RESULTS The participants generally perceived the usefulness of WAAP. While WAAP was widely used in polyclinics, GPs rarely used it. Even in polyclinics, usage varied and was associated with participants' training and practice of WAAP and task substitution to nurses. They perceived that WAAP would benefit only selected motivated patients who could understand and use it. They were hampered by language barriers in educating their multiracial patients and the perceived lack of time related to patient loads in polyclinics. The GPs lacked training and practice, role models and relied on verbal instructions as a personalised form of care delivery. CONCLUSION Family physicians generally perceived WAAP as useful, but implementation was hampered by lack of training and practice, language barriers and perceived benefits for patients.
Collapse
Affiliation(s)
- N C Tan
- SingHealth Polyclinics-Pasir Ris, 1 Pasir Ris Drive 4, #01-11, Singapore.
| | | | | | | |
Collapse
|
180
|
Takahashi M, Tan M, Kimura S, Ikeno H. Vol. 42, No. 1, pp.22-29, 2008
White blood cell fractions, oxidation index and level of stress in acne patients and healthy volunteers. Int J Cosmet Sci 2009. [DOI: 10.1111/j.1468-2494.2008.00450_4.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
181
|
Tkaczuk KR, Tait NS, Ioffe O, Rogers W, Tan M, Lesko SA, Lum ZP, Deamond SF, Shan E, Daniel JR, VanEcho DA, Ts'o PO. A retrospective study of drug response indicator test (DRIT) as a predictive test for therapeutic treatment outcomes of advanced breast cancer patients (ABC). Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-6075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #6075
We conducted a retrospective study of DRIT, an investigational diagnostic test to predict chemotherapy and endocrine therapy treatment outcomes in ABC. DRIT is a quantitative measurement of Drug Response Indicator (DRI) expression levels in formalin fixed, paraffin embedded tumor tissue. DRI chosen for each drug is related to the perceived mechanism of action of the drug. The quantitative measurement of DRI expression in the tumor tissue is based on the fluorescent dye-labeled monoclonal antibody (mAb) staining, followed by acquisition of digital images using computer-assisted microscopy, calibrated to an external standard. DRI expression measurement results in classification of the tumor as sensitive or resistant to a particular drug based on our in vitro studies of drug sensitivity/resistance in cell lines. If a tumor is classified as sensitive to a drug/s by DRIT, this predicts that the patient (Pt) will respond to treatment, while if a tumor is classified as resistant this predicts that the Pt will not respond to the drug/s therapy. Clinically the treatment outcome is classified into a responsive group (non-progressive disease,CR, PR, SD) & a non-responsive group (progressive disease, PD). The drugs & DRI tested are: capcitabine/thymidylate synthase; Taxanes /β-tubulin isoform III, trastuzamab/HER-2, Endocrine therapy/estrogen receptor, gemcitabine/ribonucleotide reductase. 51 ABC received mono or doublet therapy as first 3 lines of therapy-(80 treatments). The percent accuracy (number of accurate predictions/number of treatment interventions) for monotherapy is 87% (61/70), 100% (10/10) for doublet therapy and 89% (71/80) for all treatments. The accuracy of prediction for responsive patients is 86% (60/69) and 100% (11/11) for non responsive patients. DRIT diagnostic performance for 80 treatment outcome predictions for endocrine therapy and mono and doublet chemotherapy is as follows: sensitivity 1.00, specificity 0.55, positive predictive value 0.87, negative predictive value 1.00, and overall accuracy 0.88. For the standard of care outcomes, the favorable response rate for the 80 treatments is 75% (60/80), the potential favorable response rate with DRIT input is 86% (60/69) with 11 ineffective treatments identified by DRIT accurately 100% (11/11). Thus, DRIT input can identify effective (86%) & ineffective (100%) treatments in this cohort of ABC patients. DRIT is under developement as a diagnostic test to predict treatment outcomes prior to the selection of a particular drug for anticancer therapy, so that the most effective drug can be prescribed for an individual cancer patient. This retrospective study in ABC patients shows that DRIT has a potential to be a useful test to predict treatment outcomes.
 Supported in part by Maryland Industry Partnership Program – MIPS.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6075.
Collapse
Affiliation(s)
- KR Tkaczuk
- 1 Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
| | - NS Tait
- 1 Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
| | - O Ioffe
- 1 Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
| | - W Rogers
- 1 Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
| | - M Tan
- 1 Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
| | - SA Lesko
- 2 CCC Diagnostics LLC, Baltimore, MD
| | - ZP Lum
- 2 CCC Diagnostics LLC, Baltimore, MD
| | | | - E Shan
- 2 CCC Diagnostics LLC, Baltimore, MD
| | - JR Daniel
- 2 CCC Diagnostics LLC, Baltimore, MD
| | | | - PO Ts'o
- 2 CCC Diagnostics LLC, Baltimore, MD
| |
Collapse
|
182
|
Teoh H, Braga M, Casanova A, Drouin D, Goodman S, Harris S, Langer A, Tan M, Ur E, Woo V, Zinman B, Leiter L. Time to do more: Feedback based national glycaemic treatment optimization program can improve attainment of glycaemic targets. Can J Diabetes 2009. [DOI: 10.1016/s1499-2671(09)33044-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
183
|
Teoh H, Braga M, Casanova A, Drouin D, Goodman S, Harris S, Langer A, Tan M, Ur E, Woo V, Zinman B, Leiter L. Private drug coverage is not associated with better attainment of glycaemic targets in a Canadian glycaemic treatment optimization program. Can J Diabetes 2009. [DOI: 10.1016/s1499-2671(09)33208-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
184
|
Tan M, Abernethy L, Cooke R. Improving head growth in preterm infants--a randomised controlled trial II: MRI and developmental outcomes in the first year. Arch Dis Child Fetal Neonatal Ed 2008; 93:F342-6. [PMID: 18285378 DOI: 10.1136/adc.2007.124255] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Very preterm infants are at risk of poor growth and neurodevelopmental outcome. Illness and difficulties overcoming the challenges of feeding these infants often lead to undernutrition in the first few weeks. OBJECTIVE To explore the relationships between early nutrition, post-natal head growth, quantitative magnetic resonance imaging (MRI) and developmental outcome in the first year among infants born before 29 weeks' gestation. DESIGN Infants born before 29 weeks' gestation were randomised to receive hyperalimented or standard feeding regimen from birth to 34 weeks' postmenstrual age (PMA). The primary outcome was occipitofrontal circumference (OFC) at 36 weeks' OFC. Quantitative MRI was performed at 40 weeks' PMA. Developmental assessment using Bayley Scales of Infant Development II (BSID II) was carried out at 3 and 9 months post-term. RESULTS 109 infants survived to the end of the first year PMA. 65 infants underwent MRI scan. 81 and 71 infants were seen at 3 and 9 months post-term. Quantitative MRI findings, mental development index (MDI) and psychomotor development index (PDI) were not statistically different between the two groups. Total brain volume (TBV) at 40 weeks' PMA, MDI and PDI at 3 months post-term correlated significantly with energy deficit at 28 days of age CONCLUSIONS Improving early energy deficit in very preterm infants may promote brain growth. Quantitative MRI may have a role to play in predicting developmental outcome. Post-natal growth at 36 weeks' PMA and quantitative MRI finding at 40 weeks' PMA appear to be closely related to mental outcomes in the first year. TRIAL REGISTRATION NUMBER ISRCTN 19509258.
Collapse
Affiliation(s)
- M Tan
- Professor R W I Cooke, Neonatal Unit, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS, UK;
| | | | | |
Collapse
|
185
|
Budak M, Yücel H, Karadag M, Tan M. Experimental determination of effective resonance energies for the (n,γ) reactions of 71Ga, 75As, 164Dy, 170Er by the cadmium ratio method. ANN NUCL ENERGY 2008. [DOI: 10.1016/j.anucene.2008.01.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
186
|
Westerbeek RE, Van Rooden CJ, Tan M, Van Gils APG, Kok S, De Bats MJ, De Roos A, Huisman MV. Magnetic resonance direct thrombus imaging of the evolution of acute deep vein thrombosis of the leg. J Thromb Haemost 2008; 6:1087-92. [PMID: 18433464 DOI: 10.1111/j.1538-7836.2008.02986.x] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Accurate diagnosis of acute recurrent deep vein thrombosis (DVT) is relevant to avoid improper diagnosis and unnecessary life-long anticoagulant treatment. Compression ultrasound has high accuracy for a first episode of DVT, but is often unreliable in suspected recurrent disease. Magnetic resonance direct thrombus imaging (MR DTI) has been shown to accurately detect acute DVT. The purpose of this prospective study was to determine the MR signal change during 6 months follow-up in patients with acute DVT. PATIENTS/METHODS This study was a prospective study of 43 consecutive patients with a first episode of acute DVT demonstrated by compression ultrasound. All patients underwent MR DTI. Follow-up was performed with MR-DTI and compression ultrasound at 3 and 6 months respectively. All data were coded, stored and assessed by two blinded observers. RESULTS MR direct thrombus imaging identified acute DVT in 41 of 43 patients (sensitivity 95%). There was no abnormal MR-signal in controls, or in the contralateral extremity of patients with DVT (specificity 100%). In none of the 39 patients available at 6 months follow-up was the abnormal MR-signal at the initial acute DVT observed, whereas in 12 of these patients (30.8%) compression ultrasound was still abnormal. CONCLUSION Magnetic resonance direct thrombus imaging normalizes over a period of 6 months in all patients with diagnosed DVT, while compression ultrasound remains abnormal in a third of these patients. MR-DTI may potentially allow for accurate detection in patients with acute suspected recurrent DVT, and this should be studied prospectively.
Collapse
Affiliation(s)
- R E Westerbeek
- Department of Radiology, Haga Teaching Hospital-Leyenburg, The Hague, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
187
|
Cullen KJ, Nikitakis N, Goloubeva O, Tan M, Taylor R, Schumaker L. Effect of elevated expression of GST-π and p53 on prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone: An analysis of RTOG trials 9003 and 9501. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
188
|
Affiliation(s)
- M Tan
- The Roald Dahl EEG Department, Paediatric Neurosciences Foundation, Royal Liverpool Children's Hospital (Alder Hey), Eaton Road, Liverpool L12 2AP, UK
| | | | | |
Collapse
|
189
|
Tan M, Karaca Okusluk S. P2.106 Cognition and gait. Parkinsonism Relat Disord 2008. [DOI: 10.1016/s1353-8020(08)70337-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
190
|
Vijayaraghavan R, Yan AT, Tan M, Fitchett DH, Georgescu AA, Hassan Q, Langer A, Goodman SG. Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction. Eur Heart J 2007; 29:31-7. [DOI: 10.1093/eurheartj/ehm503] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
191
|
|
192
|
Tan M, Gu Q, He H, Pamarthy D, Semenza GL, Sun Y. SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1 alpha ubiquitination and degradation. Oncogene 2007; 27:1404-11. [PMID: 17828303 DOI: 10.1038/sj.onc.1210780] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
SAG (sensitive to apoptosis gene) or ROC2/RBX2 is the second family member of ROC1/RBX1, a component of SCF (Skp1, Cullin, F-box protein) and VCB (von Hippel-Lindau (VHL), Cullin and Elongin B/C) E3 ubiquitin ligases. SAG protected cells from hypoxia-induced apoptosis when overexpressed. We report here that SAG was subjected to hypoxia induction at the levels of mRNA and protein. Hypoxia induction of SAG was largely HIF-1alpha dependent. A consensus HIF-1-binding site, GCGTG was identified in the first intron of the SAG gene. In response to hypoxia, HIF-1 bound to this site and transactivated SAG expression. SAG transactivation required both the intact binding site in cis and HIF-1alpha in trans. On the other hand, like its family member, ROC1, SAG promoted VHL-mediated HIF-1alpha ubiquitination and degradation, which was significantly inhibited upon small interfering RNA silencing of SAG or ROC1. Furthermore, the endogenous HIF-1alpha at both basal and hypoxia-induced levels was significantly increased upon SAG silencing. Finally, SAG forms in vivo complex with Cul-5 and VHL under hypoxia condition. These results suggest an HIF-1-SAG feedback loop in response to hypoxia, as follows: hypoxia induces HIF-1 to transactivate SAG. Induced SAG then promotes HIF-1alpha ubiquitination and degradation. This feedback loop may serve as a cellular defensive mechanism to reduce potential cytotoxic effects of prolonged HIF-1 activation under hypoxia.
Collapse
Affiliation(s)
- M Tan
- Department of Radiation Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109-096, USA
| | | | | | | | | | | |
Collapse
|
193
|
Sen I, Onaran M, Guneri C, Camtosun A, Celik M, Tan M, Bozkirli I. POS-02.62: Impact of different bladder volumes on uroflowmetry parameters in benign prostatic hyperplasia. Urology 2007. [DOI: 10.1016/j.urology.2007.06.703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
194
|
Abstract
The waiting list for a kidney or simultaneous pancreas-kidney transplant is growing, and waiting times are getting longer. As a consequence, transplant candidates are dying while waiting for a transplant. In a retrospective analysis, we studied whether patients on our list who died while waiting were good candidates. From January 1, 2002, through September 30, 2004, 85 candidates on our list died. Of these, 71% were waiting for a first transplant; 62% had a current panel-reactive antibody (PRA) level of 0%. Of the 85 candidates who died, the mean (+/-SD) age was 53 +/- 11 years; mean waiting time from listing to death, 979 +/- 749 days. The most common cause of death was cardiovascular disease. Many of those candidates who died while waiting were young, first-transplant candidates with a low PRA level. But only limited information was available; prospective studies are necessary to determine whether or not they were, in fact, good candidates.
Collapse
Affiliation(s)
- V Casingal
- Department of Surgery, University of Minnesota, USA
| | | | | | | | | | | |
Collapse
|
195
|
Han FP, Liu ZL, Tan M, Hao S, Fedak G, Liu B. Mobilized retrotransposon Tos17 of rice by alien DNA introgression transposes into genes and causes structural and methylation alterations of a flanking genomic region. Hereditas 2006; 141:243-51. [PMID: 15703040 DOI: 10.1111/j.1601-5223.2004.01808.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Tos17 is a copia-like endogenous retrotransposon of rice, which can be activated by various stresses such as tissue culture and alien DNA introgression. To confirm element mobilization by introgression and to study possible structural and epigenetic effects of Tos17 insertion on its target sequences, we isolated all flanking regions of Tos17 in an introgressed rice line (Tong35) that contains minute amount of genomic DNA from wild rice (Zizania latifolia). It was found that there has been apparent but limited mobilization of Tos17 in this introgression line, as being reflected by increased but stable copy number of the element in progeny of the line. Three of the five activated copies of the element have transposed into genes. Based on sequence analysis and Southern blot hybridization with several double-enzyme digests, no structural change in Tos17 could be inferred in the introgression line. Cytosine methylation status at all seven CCGG sites within Tos17 was also identical between the introgression line and its rice parent (Matsumae)-all sites being heavily methylated. In contrast, changes in structure and cytosine methylation patterns were detected in one of the three low-copy genomic regions that flank newly transposed Tos17, and all changes are stably inherited through selfed generations.
Collapse
Affiliation(s)
- F P Han
- Laboratory of Molecular Epigenetics, Institute of Genetics & Cytology, Northeast Normal University, Changchun, PR China
| | | | | | | | | | | |
Collapse
|
196
|
Tkaczuk KH, Tait NS, Chua K, Feldman F, Lesko SA, Lun Z, Tan M, Ts’o PO. Serial monitoring for circulating cancer cells in blood samples of stage 1–4 breast cancer patients. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
623 Serial monitoring for presence, number & characterization of circulating cancer cells (CCC) may provide valuable information that may be relevant to prognosis and treatment outcomes of breast cancer patients (BCP). We conducted a serial blood sampling study at the University of Maryland in BCP with stage 1–4 breast carcinoma. 15–20 ml of venous blood were collected before the start of systemic therapy and periodically thereafter & processed using negative selection method with double-gradient centrifugation & magnetic cell sorting to remove WBCs. Digital images of FITC-positive epithelial cells were acquired with a fluorescence microscope & counted. CCC from 41 patients (Pts) were also stained with Trastuzu-mAb-532 to quantify the HER-2/neu cell surface receptor expression relative to a fluorescence standard. 105 Pts were accrued & 415 blood samples tested (median number of samples/pt; 4 (1–8). During the 24 mos. monitoring period CCC were detected in 57 of 105 pts (54%). The Table below shows that presence of >10 CCC/sample is associated with decreased survival and increased probability of having metastatic disease.(Exact chi-square test for presence vs. absence of metastatses in A, B, C, D groups, P < 0.0001; Fisher’s exact test to compare individual groups: for B vs C+ D, P < 0.001; B vs C, P=0.001). HER-2/neu expression was assessed in CCC of 25 pts (minimum of 4 CCC per sample) as compared with strongly HER-2/neu positive control cell line SKBR-3. 10 Pts were positive & 15 negative for HER-2/neu over-expression in CCC. CCC data & primary tumor data concurred in 6 of 7 Her-2/neu primary tumor tissue positive Pts & in 12 of 13 Her-2/neu primary tissue negative Pts. For 5 Pts tissue data was not available. Conclusions: Increasing CCC numbers/sample appear to correlate with adverse outcome of BCP. Our CCC Test may provide valuable information about prognosis of stage 1–4 BCP. HER-2/neu expression could be quantified in individual CCC & concurred with primary tumor data in 90% of Pts. Supported by NCI Grant CA081903 [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- K. H. Tkaczuk
- University of Maryland Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD
| | - N. S. Tait
- University of Maryland Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD
| | - K. Chua
- University of Maryland Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD
| | - F. Feldman
- University of Maryland Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD
| | - S. A. Lesko
- University of Maryland Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD
| | - Z. Lun
- University of Maryland Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD
| | - M. Tan
- University of Maryland Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD
| | - P. O. Ts’o
- University of Maryland Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD
| |
Collapse
|
197
|
Teh BT, Yang XJ, Tan M, Kim HL, Stadler W, Vogelzang NG, Amato R, Figlin R, Belldegrun A, Rogers CG. Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4503 Background: Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphological classification of PRCC into Type 1 and Type 2 tumors has been recently proposed, but its biological relevance remains uncertain. Methods: We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analysis. Comparative genomic microarray analysis (CGMA) was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples, with 15 independent tumors. Results: We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histological subtypes: Type 1, low-grade Type 2 and mixed Type 1/low-grade Type 2 tumors. The second class, with poor survival, corresponded to high-grade Type 2 tumors (n = 11). Dysregulation of G1/S and G2/M checkpoint genes were found in Class 1 and Class 2 tumors respectively, alongside characteristic chromosomal aberrations. We identified a 7-transcript predictor that classified samples on cross-validation with 97% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in Class 1 tumors, and of topoisomerase IIα in Class 2 tumors. Conclusions: We report two molecular subclasses of PRCC, which are biologically and clinically distinct, which may be readily distinguished in a clinical setting. This may also have therapeutic implications. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. T. Teh
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - X. J. Yang
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - M. Tan
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - H. L. Kim
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - W. Stadler
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - N. G. Vogelzang
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - R. Amato
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - R. Figlin
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - A. Belldegrun
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - C. G. Rogers
- Van Andel Research Institute, Grand Rapids, MI; Feinberg School of Medicine, Chicago, IL; Alexandra Hospital, Singapore, Singapore; UCLA, Los Angeles, CA; University of Chicago, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| |
Collapse
|
198
|
Tan M, Teh B. The von Hippel-Lindau gene mutation is associated with the good-prognosis profiling subtype of clear cell renal cell carcinoma. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4532 Background: The prevalence of von Hippel-Lindau (VHL) mutations in clear cell renal cell carcinoma (ccRCC) is about 30–50%. The association between VHL mutation and patient prognosis remains controversial, despite extensive in vitro research on its role in hypoxia response. We have previously reported a robust prognostic classification of ccRCC using gene expression profiling. In view of reports of activity of anti-angiogenesis agents, we studied the association of VHL mutation with tumor profiling subtypes, survival and other clinical parameters. Methods: All exons of the VHL gene in 88 ccRCC samples were sequenced. Expression profiling using oligonucleotide arrays (54,675 probe sets) was also performed, and the samples classified using hierarchical clustering. For identification of VHL mutation specific signatures, nearest shrunken centroids with internal validation was used with a 10% misclassification cutoff. Results: 35% of the samples had VHL mutations. Mutation status was not significantly associated with survival on univariate analysis (p = 0.54). Hierarchical clustering yielded two ccRCC subtypes with divergent clinical outcomes (HR = 4.13, p < 0.001). VHL mutations were significantly associated with the good-prognosis profiling subtype of ccRCC tumors (OR 3.3, p = 0.04), but no effect modification between VHL mutation and the prognostic subtypes was found (p=0.31). No standard clinical parameter was associated with VHL mutation. No significant association between VHL mutation and downstream hypoxia response gene expression, including VEGF (p = 0.14), PDGF (p = 0.5), TGF-A (p = 0.24) and GLUT1 (p = 0.45) was found. Conclusion: While VHL mutation is associated with a biologically distinct good-prognosis profiling tumor subtype, its lack of prognostic value on univariate analysis suggests an expanded study to evaluate effect modification. The absence of a specific gene classifier for VHL mutation and the lack of association between VHL gene mutation and known hypoxia response genes suggest that VHL mutations result in heterogenous tissue phenotypes. These results support molecular subtyping of ccRCC in laboratory and clinical studies; in particular, this may be critical for trials involving anti-angiogenesis agents. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Tan
- Van Andel Research Institute, Grand Rapids, MI
| | - B. Teh
- Van Andel Research Institute, Grand Rapids, MI
| |
Collapse
|
199
|
Gojo I, Meisenberg B, Guo C, Fassas A, Murthy A, Fenton R, Takebe N, Heyman M, Philips GL, Cottler-Fox M, Sarkodee-Adoo C, Ruehle K, French T, Tan M, Tricot G, Rapoport AP. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant 2006; 37:65-72. [PMID: 16247422 DOI: 10.1038/sj.bmt.1705192] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Although high-dose therapy and autologous stem cell transplant (ASCT) is superior to conventional chemotherapy for treatment of myeloma, most patients relapse and the time to relapse depends upon the initial prognostic factors. The administration of non-cross-resistant chemotherapies during the post-transplant period may delay or prevent relapse. We prospectively studied the role of consolidation chemotherapy (CC) after single autologous peripheral blood stem cell transplant (auto-PBSCT) in 103 mostly newly diagnosed myeloma patients (67 patients were < or =6 months from the initial treatment). Patients received conditioning with BCNU, melphalan+/-gemcitabine and auto-PBSCT followed by two cycles of the DCEP+/-G regimen (dexamethasone, cyclophosphamide, etoposide, cisplatin+/-gemcitabine) at 3 and 9 months post-transplant and alternating with two cycles of DPP regimen (dexamethasone, cisplatin, paclitaxel) at 6 and 12 months post-transplant. With a median follow-up of 61.2 months, the median event-free survival (EFS) and overall survival (OS) are 26 and 54.1 months, respectively. The 5-year EFS and OS are 23.1 and 42.5%, respectively. Overall, 51 (49.5%) patients finished all CC, suggesting that a major limitation of this approach is an inability to deliver all planned treatments. In order to improve results following autotransplantation, novel agents or immunologic approaches should be studied in the post-transplant setting.
Collapse
Affiliation(s)
- I Gojo
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
200
|
Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 2006; 25:3286-95. [PMID: 16407820 DOI: 10.1038/sj.onc.1209361] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Although ErbB2 is known to enhance breast cancer metastasis, the signaling events responsible for this remain elusive. Alpha-isozyme of protein kinase C (PKCalpha), which is involved in cancer development and progression, has been suggested to be activated by ErbB2 without direct evidence. In addition, the roles of PKCalpha in ErbB2-mediated cancer cell malignancy have not been clearly identified. In this study, we investigated whether ErbB2 can activate PKCalpha and determined what role PKCalpha plays in ErbB2-mediated breast cancer cell invasion. We expressed wild-type and mutant ErbB2 with altered signaling capacities in MDA-MB-435 breast cancer cells and revealed that overexpression or activation of ErbB2 in MDA-MB-435 cells upregulated and activated PKCalpha and that downregulation of ErbB2 by small-interfering RNA decreased the expression and activity of PKCalpha in BT474 breast cancer cells. These in vitro results were supported by data from breast cancer patient samples. In 150 breast cancer tumor samples, ErbB2-overexpressing tumors showed significantly higher positive rates of PKCalpha membrane immunohistochemistry staining than that of ErbB2-low-expressing tumors. Mechanistically, we found that PKCalpha is co-immunoprecipitated with Src and PKCalpha expression and activity can be decreased by Src inhibitor PP2 and by the expression of a dominant-negative mutant of Src. Moreover, ErbB2-mediated upregulation of urokinase-type plasminogen activator receptor (uPAR) is reduced by either the PKCalpha inhibitor Go6976 or the Src inhibitor PP2, and the combination of Go6976 with PP2 is superior to either agent alone in suppressing uPAR expression and cell invasion. These results demonstrate that PKCalpha is critical for ErbB2-mediated cancer cell invasion and provide valuable insights for current and future PKCalpha and Src inhibitor clinical trials.
Collapse
Affiliation(s)
- M Tan
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
| | | | | | | | | |
Collapse
|